PKMYT1激酶改善了骨髓瘤瘤中西斯丁的敏感性
Binfeng Liu1,2,3,4, Wei Li2,5, Wenchao Zhang1,2,3
1Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Signal transduction and targeted therapy
|May 20, 2025
概括
蛋白质激酶膜相关的氨酸/氨酸1 (PKMYT1) 通过破坏DNA修复,驱动骨髓瘤中西斯普拉丁耐药性. 抑制PKMYT1可以提高化疗的有效性,为骨髓瘤患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 西斯丁 (DDP) 是骨髓瘤瘤 (OS) 的首要治疗方法,但耐药性显著降低了其有效性.
- 识别DDP耐药性的机制对于改善骨髓瘤患者的治疗结果至关重要.
研究的目的:
- 为了确定骨髓瘤细胞中DDP敏感性的关键调节者.
- 阐明由已识别的调节器介导的DDP抗性的基础分子机制.
- 评估针对这些调节器的潜在治疗策略.
主要方法:
- 一个全基因组聚集定期间隔的短平行体重复 (CRISPR) 屏幕被用来识别DDP灵敏度调节器.
- 转录组测序被用来分析基因表达变化.
- 进行了体外功能测定和对患者获得的临床样本的分析.
- 研究了PKMYT1抑制对DDP敏感性和DNA损伤反应途径的影响.
主要成果:
- 蛋白质激酶膜相关的氨酸/氨酸1 (PKMYT1) 被确定为OS中DDP敏感性的关键调节者.
- 在DDP治疗后,在OS细胞中观察到PKMYT1的激活,这有助于化学抵抗.
- 沉默PKMYT1增强了OS细胞对DDP的敏感性.
- 通过化核胺1 (NPM1),PKMYT1促进化学抵抗,损害其SUMOylation,并随后阻碍DNA损伤反应因子 (BRCA1,RAP80,RAD51) 和双链断裂 (DSB) 修复.
- PKMYT1 抑制剂 RP6306 与 DDP 协同作用,增加了其细胞毒性.
结论:
- 在骨髓瘤中,PKMYT1在调解DDP耐药性方面发挥着重要作用.
- 向PKMYT1代表了一种有希望的治疗策略,以克服OS中的DDP抵抗.
- 使用DDP和PKMYT1抑制剂的联合治疗需要对骨髓瘤治疗进行进一步的临床研究.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:22PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K